drugset / Trial / NCT04385173
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
Phase 1
Unknown
12 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-03-01
- Completion
- 2024-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B7-H3CART | Cell therapy | — | Other |
| Background | Temozolomide | Small molecule | 200 mg/m2 | Oral |